Prosidion's future up in the air as Astellas begins assessing options
This article was originally published in Scrip
Astellas has begun considering strategic options for the future of its UK R&D subsidiary Prosidion, which it acquired last year as part of the purchase of OSI Pharmaceuticals but now apparently considers surplus to its core interests.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: Biomarin’s next chapter; Amgen’s obesity plans; Daiichi’s new ADC data; Acelyrin hit by clinical failure; and Skyrizi beats Stelara in Crohn’s.
In this week's podcast edition of Five Must-Know Things: the rise of Novo Nordisk; senior level changes at Novartis; Moderna’s progress against BA.2.86; major new CNS drugs coming; and Boehringer Ingelheim’s head of innovation on R&D priorities.
Following consideration by our independent expert judging panel, the final shortlist of entries has now been revealed for the Citeline Pharma Intelligence Awards Japan 2023. Join us at the event in Tokyo on 17 October!